Guggenheim analyst Seamus Fernandez raised the firm’s price target on Apogee Therapeutics (APGE) to $110 from $95 and keeps a Buy rating on the shares to reflect recent pipeline advancements. The firm, which notes it has a “bullish view” on Apogee’s approach, looks forward to learning more about the company’s development plans at Apogee’s R&D Day on Monday, December 2, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Apogee initiated with a Buy at Canaccord on APG777 ‘blockbuster potential’
- Apogee Therapeutics initiated with a Buy at Canaccord
- Apogee Therapeutics Highlights Pipeline Progress and Financials
- Apogee reports Q3 EPS, expects cash to fund operations into Q1 of 2028
- Apogee Therapeutics, Inc. (APGE) Q3 Earnings Cheat Sheet
